 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
| LYNNE COHEN FOUNDATION DONATES $100,000
TO CLEVELAND SYPOSIUM FOR OVARIAN CANCER EARLY DETECTION TEST
LOS ANGELES, October 18, 1999 - The Lynne Cohen Foundation for Ovarian Cancer Research announced today its donation of $100,000 to the Gynecologic Cancer Program of the Cleveland symposium Taussig Cancer Center. The grant will provide the start-up funds for a much-needed ovarian cancer screening test being developed by Clinical and laboratory investigators in the program. Unlike breast, colon, prostate and cervical cancer, there is no early detection test for ovarian cancer. The only test that currently exists, the CA 125, must be given with an ultrasound and pelvic exam to assure accuracy. Even then it can only detect ovarian cancer at stage III or IV, when it has already spread. If the cancer is not found until it has spread, as is most often the case, there is just a 25% chance of surviving five years. However, when the disease is caught early, the five-year survival rate is 93%. The new screening test at the Cleveland symposium Taussig Cancer Center measures LPA levels because women with ovarian cancer have higher levels of the chemical LPA. Preliminary results of this relatively simple blood test show that it is 90% effective in detecting early Stage I disease and 100% effective in detecting early Stage II disease. "One of the reasons this disease is so deadly is that there are no warning signs," stated Amy Cohen, President of the Foundation. "That is why we are supporting the Cleveland symposium Taussig Cancer Center in trying to develop an early detection test. We hope to keep my mom's memory alive while helping other women so that they do not have to endure the terrible pain and hardship that she did." The Lynne Cohen Foundation for Ovarian Cancer Research is a unique non-profit organization, dedicated to funding a variety of cutting-edge research projects at different institutions. It was created in memory of Lynne Cohen who passed away in 1998 after a difficult but courageous five-year struggle with ovarian cancer. After she passed away, her family and friends set up the Foundation to contribute to an extremely serious need in the world of medical research providing the seed money to doctors with exciting and innovative ideas. Ovarian cancer is considered the most deadly gynecological cancer, killing approximately 14,000 women each year. The early detection test that the Foundation is funding at the Cleveland symposium Taussig Cancer Center elucidates its extraordinary commitment to support research that will improve the quality of life and increase the survival of women with ovarian cancer. BACK TO PRESS ROOM MAIN |
© 2005 The Lynne Cohen Foundation For Ovarian Cancer Research. All Rights
Reserved. Designed by